- Home
- SA vs AGIO Comparison
SA vs AGIO Comparison
Compare SA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SA | AGIO |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2004 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SA | AGIO |
|---|---|---|
| Price | $32.00 | $33.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $65.00 | $38.88 |
| AVG Volume (30 Days) | 839.1K | ★ 919.3K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.13 | $22.24 |
| 52 Week High | $40.06 | $46.00 |
Technical Indicators
Market Signals| Indicator | SA | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 46.21 |
| Support Level | $30.15 | $32.54 |
| Resistance Level | $32.75 | $36.04 |
| Average True Range (ATR) | 1.80 | 1.21 |
| MACD | -0.10 | 0.12 |
| Stochastic Oscillator | 44.11 | 25.75 |
Price Performance
Historical ComparisonAbout SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.